ID
29574
Beskrivning
Study ID: 104385 Clinical Study ID: RES104385 Study Title: A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00318630 https://clinicaltrials.gov/ct2/show/NCT00318630 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia Study Indication: Asthma This ODM-file contains Adverse Events: Serious Adverse Events (Part of "End of Study").
Länk
https://clinicaltrials.gov/ct2/show/NCT00318630
Nyckelord
Versioner (1)
- 2018-04-06 2018-04-06 - Sarah Riepenhausen
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
6 april 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
GSK Influence of PPAR gamma agonist vs. Placebo on allergen-induced late asthmatic response NCT00318630
Adverse Events: Serious Adverse Events
- StudyEvent: ODM
Beskrivning
Serious Adverse Events - Section 1
Alias
- UMLS CUI-1
- C1519255
Beskrivning
DEFINITION A serious adverse event is any untoward medical occurrence that, at any dose: a) results in death. b) is life-threatening. The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe. c) requires hospitalisation or prolongation of existing hospitalisation. In general, hospitalisation signifies that the subject has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or out-patient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event is ’serious’. When in doubt as to whether ’hospitalisation’ occurred or was necessary, the AE should be considered ’serious’. Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE. d) results in disability/incapacity. The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption. e) is a congenital anomaly/birth defect. f) other: Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation, or development of drug dependency or drug abuse. If yes, record the details in the other items of this itemgroup and the other Serious Adverse Events itemgroups.
Datatyp
text
Alias
- UMLS CUI [1]
- C1519255
Beskrivning
Record one SAE diagnosis per line, or a sign/symptom if the diagnosis is not available. If a diagnosis subsequently becomes available, this then should be entered and the sign/symptom crossed out, initialled and dated by the investigator. A separate form should be used for each SAE however if multiple SAEs which are temporally or clinically related are apparent at the time of initial reporting then these may be reported on the same page. Ensure that no medical or investigational procedures are captured in the Serious Adverse Event Sections. Death should not be recorded as an SAE but should be recorded as the outcome of an SAE. The condition that resulted in the death should be recorded as the SAE.
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0011900
- UMLS CUI [2,1]
- C0877248
- UMLS CUI [2,2]
- C0037088
Beskrivning
Record the start date of the first occurrence of the SAE. Start dates must be provided for the reporting of adverse event data. If the exact date is not known, liaise with the investigator to ensure that a best estimate is provided.
Datatyp
date
Alias
- UMLS CUI [1]
- C2697888
Beskrivning
Record the start time of the SAE.
Datatyp
time
Alias
- UMLS CUI [1,1]
- C1301880
- UMLS CUI [1,2]
- C0877248
Beskrivning
All SAEs must be followed until the events are resolved, the condition stabilises, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was ’Recovered/Resolved’ or ’Recovered/Resolved with sequelae’. If the SAE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as ’Not recovered/Not resolved’ or ’Recovering/Resolving’. Also enter ’Not recovered/Not resolved’ if the SAE was ongoing at the time of death, but was not the cause of death. Enter fatal for the SAE which was the direct cause of death. Confirm that any SAEs marked as Recovering/Resolving or Not recovered/Not resolved have been followed up for details of resolution.
Datatyp
integer
Alias
- UMLS CUI [1]
- C1705586
Beskrivning
Record the end date. This is the date the SAE Recovered/Resolved, or if the outcome was fatal, record the date the subject died (Date of Death). If the event Recovered/Resolved with sequelae, enter the date the subject’s medical condition resolved or stabilised. Leave blank if the SAE is ’Not recovered/Not resolved’ or ’Recovering/Resolving’.
Datatyp
date
Alias
- UMLS CUI [1,1]
- C0806020
- UMLS CUI [1,2]
- C1518404
Beskrivning
End Time
Datatyp
time
Alias
- UMLS CUI [1]
- C2826658
Beskrivning
Mild = An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities. Moderate = An event that is sufficiently discomforting to interfere with normal everyday activities. Severe = An event that prevents normal everyday activities. Not applicable = those event(s) where intensity is meaningless or impossible to determine (i.e., blindness and coma).
Datatyp
text
Alias
- UMLS CUI [1]
- C1710066
Beskrivning
Investigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. Dose reduced = Dose is reduced for one or more investigational product(s). Dose increased = Dose increased for one or more investigational product(s). Dose not changed = Investigational product(s) continues even though an adverse event has occurred. Dose interrupted = Administration of one or more investigational product(s) was stopped temporarily but then restarted. Not applicable = Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing).
Datatyp
text
Alias
- UMLS CUI [1]
- C2826626
Beskrivning
Indicate ’Yes’ if the event(s) were directly responsible for the subject’s withdrawal as indicated on the Study Conclusion page, otherwise indicate ’No’. If yes, complete Study Conclusion form and pick Adverse event as reason for withdrawal.
Datatyp
text
Alias
- UMLS CUI [1,1]
- C1710677
- UMLS CUI [1,2]
- C1519255
Beskrivning
It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. ’A reasonable possibility’ is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support ’a reasonable possibility’ include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.
Datatyp
text
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C0013230
- UMLS CUI [1,3]
- C0439849
Beskrivning
If Yes, summarise findings in Section 11 Narrative Remarks of the SAE itemgroups.
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0004398
- UMLS CUI [1,2]
- C1519255
Beskrivning
Serious Adverse Events - Section 2: Seriousness
Alias
- UMLS CUI-1
- C1519255
- UMLS CUI-2
- C0439793
Beskrivning
A
Datatyp
boolean
Alias
- UMLS CUI [1]
- C1705232
Beskrivning
B
Datatyp
boolean
Alias
- UMLS CUI [1]
- C1517874
Beskrivning
C
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C0019993
- UMLS CUI [2,1]
- C1519255
- UMLS CUI [2,2]
- C0745041
Beskrivning
D
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C3176592
- UMLS CUI [1,2]
- C1274040
- UMLS CUI [1,3]
- C1519255
Beskrivning
E
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C0000768
- UMLS CUI [1,2]
- C1519255
Beskrivning
F Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation, or development of drug dependency or drug abuse. If yes, specify in the item "Other, specify".
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C1519255
Beskrivning
If yes in item "other" of itemgroup SAE - Section 2: Seriousness
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C1519255
Beskrivning
Serious Adverse Events - Section 3: Demography Data
Alias
- UMLS CUI-1
- C1828479
- UMLS CUI-2
- C0011298
- UMLS CUI-3
- C1519255
Beskrivning
Serious Adverse Events - Section 4
Alias
- UMLS CUI-1
- C1519255
Beskrivning
If Investigational Product was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) Were Administered?
Datatyp
text
Alias
- UMLS CUI [1,1]
- C2945760
- UMLS CUI [1,2]
- C1519255
Beskrivning
Serious Adverse Events - Section 5: Possible Causes of SAE Other Than Investigational Products
Alias
- UMLS CUI-1
- C0085978
- UMLS CUI-2
- C1519255
- UMLS CUI-3
- C0304229
- UMLS CUI-4
- C3845511
Beskrivning
Disease under study
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C0012634
Beskrivning
If yes, record in Section 6.
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C0009488
Beskrivning
Lack of efficacy
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C0235828
Beskrivning
Withdrawal of investigational product(s)
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C0304229
- UMLS CUI [1,4]
- C2349954
Beskrivning
If yes, record in Section 8.
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C2347852
- UMLS CUI [1,2]
- C1519255
- UMLS CUI [1,3]
- C0085978
Beskrivning
e.g., procedures
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C2348568
- UMLS CUI [1,2]
- C0085978
- UMLS CUI [1,3]
- C1519255
Beskrivning
If yes, specify in "other, specify" item.
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C3840932
- UMLS CUI [1,2]
- C1519255
Beskrivning
If yes in item "other" of this itemgroup, specify.
Datatyp
text
Alias
- UMLS CUI [1,1]
- C3840932
- UMLS CUI [1,2]
- C1519255
Beskrivning
Serious Adverse Events - Section 6: Relevant medical conditions
Alias
- UMLS CUI-1
- C1828479
- UMLS CUI-2
- C0012634
- UMLS CUI-3
- C1519255
Beskrivning
Relevant past or current medical conditions
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0262926
- UMLS CUI [1,2]
- C1519255
- UMLS CUI [2,1]
- C3899485
- UMLS CUI [2,2]
- C1519255
Beskrivning
Date of onset
Datatyp
date
Alias
- UMLS CUI [1,1]
- C0574845
- UMLS CUI [1,2]
- C0009488
Beskrivning
Condition Present at Time of the SAE?
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0012634
- UMLS CUI [1,2]
- C0150312
- UMLS CUI [1,3]
- C1519255
Beskrivning
Fill in if condition was not present at time of SAE.
Datatyp
date
Alias
- UMLS CUI [1,1]
- C2745955
- UMLS CUI [1,2]
- C0012634
- UMLS CUI [1,3]
- C0011008
Beskrivning
Serious Adverse Events - Section 7: Other relevant risk factors
Alias
- UMLS CUI-1
- C0035648
- UMLS CUI-2
- C1519255
Beskrivning
Serious Adverse Events - Section 8: Relevant concomitant medication
Alias
- UMLS CUI-1
- C1519255
- UMLS CUI-2
- C2347852
Beskrivning
Include details of any concomitant medication(s) which may have contributed to the event. Trade name preferred.
Datatyp
text
Alias
- UMLS CUI [1,1]
- C2360065
- UMLS CUI [1,2]
- C2347852
Beskrivning
Dose
Datatyp
float
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C2347852
Beskrivning
Unit
Datatyp
text
Alias
- UMLS CUI [1,1]
- C1519795
- UMLS CUI [1,2]
- C2347852
- UMLS CUI [1,3]
- C1519255
Beskrivning
Frequency
Datatyp
text
Alias
- UMLS CUI [1,1]
- C3476109
- UMLS CUI [1,2]
- C2347852
- UMLS CUI [1,3]
- C1519255
Beskrivning
Route
Datatyp
text
Alias
- UMLS CUI [1]
- C2826730
Beskrivning
Taken prior to study?
Datatyp
text
Alias
- UMLS CUI [1]
- C2826667
Beskrivning
Start Date
Datatyp
date
Alias
- UMLS CUI [1]
- C2826734
Beskrivning
Stop Date
Datatyp
date
Alias
- UMLS CUI [1,1]
- C0806020
- UMLS CUI [1,2]
- C2347852
Beskrivning
Ongoing medication?
Datatyp
text
Alias
- UMLS CUI [1]
- C2826666
Beskrivning
Reason for medication
Datatyp
text
Alias
- UMLS CUI [1]
- C2826696
Beskrivning
Serious Adverse Events - Section 9: Details of investigational Products
Alias
- UMLS CUI-1
- C1519255
- UMLS CUI-2
- C0304229
Beskrivning
Start Date Treatment period 1
Datatyp
date
Alias
- UMLS CUI [1,1]
- C3173309
- UMLS CUI [1,2]
- C0304229
Beskrivning
Start Date Treatment period 2
Datatyp
date
Alias
- UMLS CUI [1,1]
- C3173309
- UMLS CUI [1,2]
- C0304229
Beskrivning
Stop Date Treatment period 1
Datatyp
date
Alias
- UMLS CUI [1,1]
- C0806020
- UMLS CUI [1,2]
- C0304229
Beskrivning
Stop Date Treatment period 2
Datatyp
date
Alias
- UMLS CUI [1,1]
- C0806020
- UMLS CUI [1,2]
- C0304229
Beskrivning
Treatment blind
Datatyp
text
Alias
- UMLS CUI [1,1]
- C2347038
- UMLS CUI [1,2]
- C0449438
Beskrivning
Serious Adverse Events - Section 10: Details of relevant assessments
Alias
- UMLS CUI-1
- C2700391
- UMLS CUI-2
- C0011900
- UMLS CUI-3
- C1519255
Beskrivning
Serious Adverse Events - Section 11: Narrative Remarks
Alias
- UMLS CUI-1
- C0947611
- UMLS CUI-2
- C1519255
Beskrivning
Narrative Remarks
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0947611
- UMLS CUI [1,2]
- C1519255
Beskrivning
confirming that the data on the SAE pages are accurate and complete
Datatyp
text
Alias
- UMLS CUI [1]
- C2346576
Beskrivning
Date of Investigator signature
Datatyp
date
Alias
- UMLS CUI [1,1]
- C2346576
- UMLS CUI [1,2]
- C0011008
Beskrivning
Investigator's Name
Datatyp
text
Alias
- UMLS CUI [1]
- C2826892
Similar models
Adverse Events: Serious Adverse Events
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0237753 (UMLS CUI [1,2])
C0011900 (UMLS CUI [1,2])
C0877248 (UMLS CUI [2,1])
C0037088 (UMLS CUI [2,2])
C0877248 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
C1519255 (UMLS CUI [1,2])
C0439793 (UMLS CUI-2)
C0019993 (UMLS CUI [1,2])
C1519255 (UMLS CUI [2,1])
C0745041 (UMLS CUI [2,2])
C1274040 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0011298 (UMLS CUI-2)
C1519255 (UMLS CUI-3)
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI-2)
C0304229 (UMLS CUI-3)
C3845511 (UMLS CUI-4)
C0877248 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,3])
C0877248 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0877248 (UMLS CUI [1,2])
C0235828 (UMLS CUI [1,3])
C0877248 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C2349954 (UMLS CUI [1,4])
C1519255 (UMLS CUI [1,2])
C0085978 (UMLS CUI [1,3])
C0085978 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0012634 (UMLS CUI-2)
C1519255 (UMLS CUI-3)
C1519255 (UMLS CUI [1,2])
C3899485 (UMLS CUI [2,1])
C1519255 (UMLS CUI [2,2])
C0009488 (UMLS CUI [1,2])
C0150312 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
C0012634 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C1519255 (UMLS CUI-2)
C1519255 (UMLS CUI [1,2])
C2347852 (UMLS CUI-2)
C2347852 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
C2347852 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
C2347852 (UMLS CUI [1,2])
C0304229 (UMLS CUI-2)
C0304229 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,2])
C0449438 (UMLS CUI [1,2])
C0011900 (UMLS CUI-2)
C1519255 (UMLS CUI-3)
C0011900 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
C1519255 (UMLS CUI-2)
C1519255 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])